Literature DB >> 16906764

T-state inhibitors of E. coli aspartate transcarbamoylase that prevent the allosteric transition.

Sabrina Heng1, Kimberly A Stieglitz, Joby Eldo, Jiarong Xia, James P Cardia, Evan R Kantrowitz.   

Abstract

Escherichia coli aspartate transcarbamoylase (ATCase) catalyzes the committed step in pyrimidine nucleotide biosynthesis, the reaction between carbamoyl phosphate (CP) and l-aspartate to form N-carbamoyl-l-aspartate and inorganic phosphate. The enzyme exhibits homotropic cooperativity and is allosterically regulated. Upon binding l-aspartate in the presence of a saturating concentration of CP, the enzyme is converted from the low-activity low-affinity T state to the high-activity high-affinity R state. The potent inhibitor N-phosphonacetyl-l-aspartate (PALA), which combines the binding features of Asp and CP into one molecule, has been shown to induce the allosteric transition to the R state. In the presence of only CP, the enzyme is the T structure with the active site primed for the binding of aspartate. In a structure of the enzyme-CP complex (T(CP)), two CP molecules were observed in the active site approximately 7A apart, one with high occupancy and one with low occupancy. The high occupancy site corresponds to the position for CP observed in the structure of the enzyme with CP and the aspartate analogue succinate bound. The position of the second CP is in a unique site and does not overlap with the aspartate binding site. As a means to generate a new class of inhibitors for ATCase, the domain-open T state of the enzyme was targeted. We designed, synthesized, and characterized three inhibitors that were composed of two phosphonacetamide groups linked together. These two phosphonacetamide groups mimic the positions of the two CP molecules in the T(CP) structure. X-ray crystal structures of ATCase-inhibitor complexes revealed that each of these inhibitors bind to the T state of the enzyme and occupy the active site area. As opposed to the binding of Asp in the presence of CP or PALA, these inhibitors are unable to initiate the global T to R conformational change. Although the best of these T-state inhibitors only has a K(i) value in the micromolar range, the structural information with respect to their mode of binding provides important information for the design of second generation inhibitors that will have even higher affinity for the active site of the T state of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16906764     DOI: 10.1021/bi0601095

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.

Authors:  Joby Eldo; Sabrina Heng; Evan R Kantrowitz
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

Review 2.  Allostery and cooperativity in Escherichia coli aspartate transcarbamoylase.

Authors:  Evan R Kantrowitz
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

3.  Submicromolar phosphinic inhibitors of Escherichia coli aspartate transcarbamoylase.

Authors:  Laëtitia Coudray; Evan R Kantrowitz; Jean-Luc Montchamp
Journal:  Bioorg Med Chem Lett       Date:  2008-12-06       Impact factor: 2.823

4.  Synthesis and in vitro evaluation of aspartate transcarbamoylase inhibitors.

Authors:  Laëtitia Coudray; Anne F Pennebaker; Jean-Luc Montchamp
Journal:  Bioorg Med Chem       Date:  2009-09-30       Impact factor: 3.641

Review 5.  From Genome to Structure and Back Again: A Family Portrait of the Transcarbamylases.

Authors:  Dashuang Shi; Norma M Allewell; Mendel Tuchman
Journal:  Int J Mol Sci       Date:  2015-08-12       Impact factor: 5.923

Review 6.  Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase.

Authors:  Chao Wang; Arne Krüger; Xiaochen Du; Carsten Wrenger; Matthew R Groves
Journal:  Front Cell Infect Microbiol       Date:  2022-03-04       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.